SaschaA.TuchmanMDMHS
Hematology • Chapel Hill, NCAssociate Professor; Director of Multiple Myeloma and Amyloidosis Program; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Dr. Tuchman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
101 Manning Dr
Chapel Hill, NC 27514Phone+1 984-974-0000Fax+1 984-974-8612- Is this information wrong?
Education & Training
Duke University School of MedicineMHS, Clinical Research Training Program, 2008 - 2016
Duke University HospitalFellowship, Hematology and Medical Oncology, 2006 - 2010- Duke University HospitalResidency, Internal Medicine, 2003 - 2006
Georgetown University School of MedicineClass of 2003
Certifications & Licensure
NC State Medical License 2003 - 2024- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma Start of enrollment: 2012 Dec 19
- Geriatric Assessments in Senior Adults With Multiple Myeloma Start of enrollment: 2012 Sep 01
- A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma Start of enrollment: 2013 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Geriatric assessment-guided interventions for older adults with multiple myeloma: A feasibility and acceptability study.Deal, A., Nyrop, K., Logan, M., Mangieri, N., Strayhorn, M., Miller, J., Jensen, C., Muss, H., Lichtman, E., Rubinstein, S., Tuchman, S.> ;Journal of Geriatric Oncology. 2024 Mar 1
- 2 citationsSelinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.Gary J Schiller, Brea C Lipe, Nizar J Bahlis, Sascha A Tuchman, William I Bensinger, Heather J Sutherland, Suzanne Lentzsch, Muhamed Baljevic, Darrell White, Rami Kotb...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Sep 1
- Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis.Morie Gertz, Rafat Abonour, Sarah N Gibbs, Muriel Finkel, Heather Landau, Suzanne Lentzsch, Grace Lin, Anuj Mahindra, Tiffany Quock, Cara Rosenbaum, Michael Rosenzweig...> ;Clinicoeconomics and Outcomes Research. 2023 Jan 1
- Join now to see all
Abstracts/Posters
- Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...Sascha A Tuchman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple MyelomaSascha A Tuchman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)Sascha A Tuchman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
How COVID-19 Vaccines Were Made so Quickly Without Cutting CornersJune 29th, 2021
Professional Memberships
- Member
Hospital Affiliations
University of North Carolina HospitalsChapel Hill, North Carolina
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
